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Abstract
The understanding of how environmental exposures interact with genetics in central nervous system
dysfunction has gained great momentum in the last decade. Seminal findings have been uncovered
in both mammalian and non-mammalian model in large result of the extraordinary conservation of
both genetic elements and differentiation processes between mammals and non-mammalians.
Emerging model organisms, such as the nematode and zebrafish have made it possible to assess the
effects of small molecules rapidly, inexpensively, and on a miniaturized scale. By combining the
scale and throughput of in vitro screens with the physiological complexity and traditional animal
studies, these models are providing relevant information on molecular events in the etiology of
neurodegenerative disorders. The utility of these models is largely driven by the functional
conservation seen between them and higher organisms, including humans so that knowledge obtained
using non-mammalian model systems can often provide a better understanding of equivalent
processes, pathways, and mechanisms in man. Understanding the molecular events that trigger
neurodegeneration has also greatly relied upon the use of tissue culture models.
The purpose of this summary is to provide-state-of-the-art review of recent developments of non-
mammalian experimental models and their utility in addressing issues pertinent to neurotoxicity
(Caenorhabditis elegans and Danio rerio). The synopses by Aschner and Levin summarize how
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genetic mutants of these species can be used to complement the understanding of molecular and
cellular mechanisms associated with neurobehavioral toxicity and neurodegeneration. Next, studies
by Suñol and Olopade detail the predictive value of cultures in assessing neurotoxicity. Suñol and
colleagues summarize present novel information strategies based on in vitro toxicity assays that are
predictive of cellular effects that can be extrapolated to effects on individuals. Olopade and colleagues
describe cellular changes caused by sodium metavanadate (SMV) and demonstrate how rat primary
astrocyte cultures can be used as predicitive tools to assess the neuroprotective effects of antidotes
on vanadium-induced astrogliosis and demyelination.
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C. Elegans as an Alternative Model in Toxicology
Caenorhabditis elegans in Neurotoxicology Studies
The search for experimental models that allow live in vivo analysis in the toxicological field
has led to the use of several invertebrate organisms. Caenorhabditis elegans (C. elegans) has
demonstrated great advantages in providing insights into the mechanisms of toxicity and
neuronal injury. The codification of the complete genome revealed the extraordinary
conservation of its genome with mammals (60–80% homology) [1] and studies indicating that
worms and mammals share similar biosynthetic and metabolic pathways provide justification
for its relevance in the toxicological field.
C. elegans has a small size (adults are ~1 mm long), ease of maintenance, ability to be frozen
and stored, speedy generation time (3 days), short life span, and large brood size (>300 progeny
per hermaphrodite). All these features provide a limitless supply of worms for cellular,
molecular, and genetic analyses. The transparency of C. elegans along with the ease of
constructing reporter gene fusions facilitates the visualization of neuronal morphology and
protein expression patterns within the living system. Furthermore, the intensely studied
genome, complete cell lineage map, knock-out libraries, and established genetic
methodologies, including mutagenesis, RNAi and transgenesis, provide a variety of options
for manipulating and performing molecular analyses in C. elegans.
At its first inception, the C. elegans platform was developed as an experimental model to study
nervous system development [2]. A complete three-dimensional map of the 302-cell nervous
system provides the resources for identifying most synapses between neurons [3] and green
fluorescent protein (GFP) reporter strains have been generated to allow for the observation of
different neuronal populations, for example the dat-1∷GFP fusion allows for the observation
of all 8 dopaminergic neurons in the worm (Figure 1). The extensive knowledge of the nervous
system has been exploited in the investigation of C. elegans and has allowed for the study of
various neurodegenerative disorders, such as Duchenne muscular dystrophy (DMD),
Parkinson's disease, Huntington's disease and Alzheimer's disease. An example is the
DYSTROPHIN gene, responsible for DMD, which is conserved in C. elegans and the study
of mutants has revealed progressive muscle degeneration [4]. Exposure of C. elegans to 1-
methyl-4-phenylpyridinium (MPP+) [5] or 6-hyrdroxydopamine (6-OHDA) [6] mimics
Parkinson's disease as both of these induce damage to the dopaminergic nervous system.
Expression of polyQ Huntingtin variants in C. elegans has led to discoveries revealing gene
interactions with Huntingtin, axonal defects and protein aggregation, thereby furthering our
understanding of Huntington's disease [7,8]. The investigation into Alzheimer's disease has
been advanced with mutant worms expressing human beta-amyloid precursor protein
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(betaAPP) or TAU, allowing researchers to develop insights into disease progression and
discover how other genes are involved [9].
C. elegans has also been used as a model to elucidate the toxicity and toxicological mechanisms
of a variety of metals [10]. The toxicity of aluminum, arsenic, barium, cadmium, copper,
chromium, lead, mercury, uranium, and zinc has been investigated in the C. elegans model
system, in which behavioral, morphological, and developmental alterations were observed
upon toxicant exposure [11–13]. For instance, feeding behavior, thrashing, and pharyngeal
pumping are behavioral endpoints that allow examination of the involvement of specific
neuronal networks affected by different metals and studies have indicated a decrease in these
endpoints. Various GFP reporters have been used to demonstrate changes in expression. For
example, metallothioneins are upregulated upon exposure to cadmium [14].
Paraquat, rotenone, organophosphates, and other pesticides have also been assessed in the C.
elegans model, enlightening researchers to the novel neurotoxic mechanisms through which
these agents exert their effects [11]. Strains of C. elegans have been generated that have either
increased [15] or decreased [16] sensitivity to paraquat. Although the identities of many of the
proteins encoded by the genes that cause these alterations are yet unknown, researchers have
found that alterations in antioxidants such as superoxide dismutase can cause alterations in the
response of C. elegans to paraquat. Specifically, it has been found that mutants that lack these
enzymes display increased sensitivity [17] while mutants that overexpress these enzymes
display decreased sensitivity [18,19].
C. elegans is an ideal model to use to address the increased interest in the use of high-throughput
approaches to reproducibly and efficiently screen various chemicals. High-throughput
screening tools in C. elegans studies include computer tracking software to assess behavior
and biosorters and microfluidics to manipulate large numbers of worms with great speed,
efficiency, and precision [20,21].
In summary, C, elegans is a valuable model for use in biological research, especially
toxicology. The use of worms in the toxicological field demonstrates great potential for
revealing toxicity mechanisms which elude investigators using other models. The findings of
numerous C. elegans studies have been reported and reviewed for the scientific community
[11,21,22]. Understanding mechanisms of toxicity will help to elucidate ways in which new
therapeutics can be used to mitigate the adverse health effects of various toxicants.
Behavioral Analysis of Xenobiotics in Zebrafish
Introduction
Zebrafish can provide a useful complementary model for developmental neurotoxicology to
provide important mechanistic and screening information in combination with in vitro cell-
based models, invertebrate models such as c. Elegans and drosophila as well as classic
mammalian rodent models and epidemiological studies. Zebrafish have a rich array of tools
with which determine the molecular biology of neurodevelopment and mal-development.
There are a great many zebrafish mutants with which to determine key genomic factors for the
developmental process. The use of morpholino techniques to transiently suppress specific
molecular components during early development is particularly powerful in studies of
developmental neurotoxicology. In addition, since zebrafish have a clear chorion reporter
systems can be used to highlight individual components of the nervous system nervous system
development can be visualized continuously and the impact of developmental neurotoxicants
on developing neural processes can be determined. These elegant tools to study molecular and
cellular processes in a temporally and anatomically intact model can be powerful for
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determining critical mechanisms of neurobehavioral toxicity if valid, sensitive, reliable and
efficient measures of neurobehavioral function can be developed.
Recently, a variety of laboratories including ours have developed tests of learning and memory,
stress response and sensorimotor reactivity for zebrafish, which are sensitive to drug and
toxicant effects, similar to those seen in classic rodent assays and humans. The neurobehavioral
test battery developed to date in our laboratory includes tests of swimming activity in newly
hatched fish, and in adults' sensorimotor response, exploratory behavior and stress response as
well as learning and memory. These tests have proven to be sensitive to toxicant and
pharmacological effects and with some the efficiency of the tests are enhanced by automated
computerized video analysis.
Behavioral Analyses in Zebrafish
Swimming Activity in Newly Hatched Fish—Spontaneous swimming activity can be
quantified in zebrafish during the early period after hatching for a rapid read on behavioral
consequences of developmental toxicant exposure. We found that low-dose (0.029 and 0.29
μM, 10 and 100 ml/l) exposure during the first five days after fertilization to the
organophosphate pesticide chlorpyrofos caused significant reductions in locomotor activity in
young zebrafish tested on days 6 and 9 after fertilization [23]. That study used hand scoring of
videotapes of the fish swimming activity in a three-minute session. More recently we have
reproduced the same result using a computerized video tracking system (Noldus EthoVision,
Wageningen, The Netherlands).
Sensorimotor Response—A rapid, intense sensory stimulus will in most species produce
a sudden motor reaction. The same is true in zebrafish. We have developed a test in which a
sudden tactile stimulus from a tap produced by a solenoid on the bottom of the test environment
produces a flurry of swimming activity in the fish, an effect, which shows habituation or
lessened response with repeated exposure. This sensorimotor response test has proven to be
sensitive to the persisting effects of developmental exposure to the organophosphate pesticide
chlorpyrifos. Since chlorpyrifos inhibits acetylcholinesterase (AChE) and thus acts as an
indirect cholinergic agonist we also tested the effects of developmental exposure to direct
cholinergic agonists for nicotinic and muscarinic acetylcholine receptors nicotine and
pilocarpine [24]. All three of these treatments during the first five days after fertilization
produce significant increase in sensorimotor response when the fish were later tested as adults
but chlorpyrifos was effective at a much lower dose (0.29 μM) than either nicotine (15 μM) or
pilocarpine (1,000 μM) [24].
Exploratory Behavior and Stress Response—When introduced into a novel
environment zebrafish will dive to the bottom of the tank in what is likely a predation escape
response. Gradually, over time the fish swim increasingly to the higher levels of the tank
[25]. This effect is specific to the fish being introduced into a novel tank. Placement into a
familiar tank does not produce this effect [26]. The novel tank diving response is reduced by
anxiolytic drugs diazepam and buspirone, but not by chlordiazepoxide [26]. Nicotine, which
has been shown to have anxiolytic effects in mammals including humans also significantly
reduces the novel tank diving response, an effect which is reversed by co-administration of
nicotinic antagonists [25,27]. Recently, we have found that 0.29 μM of chlorpyrifos during the
first five days after fertilization caused a significant increase in swimming activity in the novel
tank diving task as well as significantly less of the normal diving response when the fish were
tested as adults after early developmental exposure [26].
Learning and Memory—Zebrafish learn spatial and color discrimination as well as spatial
alternation as assessed in a three-chamber test tank we have developed [23,28]. Nicotine
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significantly improves both spatial learning and memory in this test paradigm [23,24,29]. The
nicotine-induced learning improvement has been shown to be related to increases in brain
dopamine activity [24]. The nicotinic antagonist mecamylamine blocks both the nicotine-
induced learning improvement and the nicotine-induced increase in dopamine metabolite
[24].
With regard to developmental neurotoxicity, we have found that 0.029 or 0.29 μM of
chlorpyrifos in the tank water of zebrafish for the first five days after fertilization causes long-
term impairment in memory assessed by the delayed spatial alternation task when the fish were
tested as adults [30]. These chlorpyrifos doses had a biphasic effect on swimming speed in the
memory test with the lower dose significantly slowing response speed and the higher dose
causing significant hyperactivity. To test the impact of inhibition of the AChE inhibition on
these behavioral functions we produced a zebrafish morpholino, which roughly matched the
degree of AChE inhibition by 0.29μM of CPF in the tank water for the first five days after
fertilization (Figure 2). When these fish and their controls were tested in the three-chamber
spatial alternation task when they were adults, the AChE morpholino fish had a significant
impairment in memory relative to controls, quite similar to the chlorpyrifos exposed fish
(Figure 3) indicating that it was the inhibition of AChE by chlorpyrifos which was sufficient
to produce the memory impairment. Interestingly, the effect of the AChE morpholino on
response speed did not match the effect of 0.29 μM of chlorpyrifos. The morpholino matching
the same degree of AChE inhibition as 0.29 μM of chlorpyrifos did not produce hyperactivity
as did 0.29 μM chlorpyrifos. If anything there was a slight reduction in speed.
These studies show that zebrafish models can provide useful neurobehavioral information
concerning the potentially adverse effects of developmental toxicant exposure. Zebrafish can
serve as a translational vertebrate model between cell-based and invertebrate and mammalian
models providing screening of compounds as well as mechanistic information concerning
developmental neurobehavioral toxicity. The development of a neurobehavioral test battery
for zebrafish will bring these advantages to bear for functional neurotoxicity.
A Way Forward for Using In Vitro Neurotoxicity Models in Acute Toxicity
Testing Strategy: Update on the FP6 Integrated Project ACuteTox
Introduction
Toxicity risk assessment for chemical-induced human health hazards relies mainly on data
obtained from animal experimentation, human studies and epidemiology. Accepted toxicity
testing since 2001 includes regulations that take into account the concepts of Refining and
Reducing animal experimentation: the Fixed Dose Procedure (FDP, TG 420), the Acute Toxic
Class Method (ATCM, TG 423), and the Up-and-Down Procedure (UDP, TG 425). In 2007,
the US National Academies proposed that toxicity testing in the 21st century should take
advantage of the understanding of “toxicity pathways” (the cellular response pathways that
underlie adverse health effects when they are sufficiently perturbed). Therefore, they
recommend using “a predictive strategy based on in vitro toxicity assays which predict cellular
level effects that can be extrapolated to effects on individuals” (NRC, 2007). In 2005, the
European Union supported the ACuteTox project, which has set the very ambitious overall
objective of developing an in-vitro test strategy sufficiently robust and powerful to replace in-
vivo testing for predicting acute toxicity of chemicals. The ACuteTox project aims to improve
the previously estimated correlation between in vitro basal cytotoxicity and rodent LD50 values
[31], to a level sufficient enough to ensure a valid prediction of human acute toxicity. The core
of the ACuteTox project is composed from the generation of a high quality in vivo data base,
the generation of a high quality in vitro data base, and the compilation of cell systems and
endpoints. In vitro data include those obtained in cytotoxicity assays and in specific in vitro/
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in silico assays for biokinetics, metabolism and organ toxicity (hepatotoxicity, nephrotoxicity
and neurotoxicity) [32]. All this information is stored in a data base that will be publicly
available on completion of the project. About 60 reference chemicals including pesticides,
pharmaceuticals and industrial chemicals, for which data on their acute human toxicity do exist,
have been tested. The linear regression analysis between cytotoxicity data (Neutral red uptake
(NRU) assay in the mouse fibroblast 3T3 cell line) and human lethal blood concentration
(LC50) gave an explained variance R2 = 0.56 for the reference chemicals [33]. It is foreseen
that the integration of biokinetic, metabolism and organ specific toxicity data will provide alerts
(against the exclusive use of cytotoxicity data) and correctors (algorithms to be used) for the
efficient use of an in vitro-based testing strategy for predicting human acute toxicity.
The ACuteTox Project as a Predictive Tool for Neurotoxicity Assessment
The nervous system is particularly vulnerable to chemical exposure; its complexity results in
multiple potential target sites with different toxicity features. Acute human toxicity related to
adverse neuronal function is mainly a result of over-excitation or depression of the peripheral
or central nervous system (CNS). The major molecular and cellular mechanisms involved in
such effects include GABAergic, glutamatergic and cholinergic neurotransmission, regulation
of cell and mitochondrial membrane potential, and those critical for maintaining CNS
functionality, such as controlling cell energy. Up to 57 neural endpoints, including those related
with the above mechanisms and others that specifically identify neural types (neurons,
astrocytes and microglia) or a cascade of multiple targets (induction of stress and apoptotic
gene biomarkers), have been determined in primary cultured rodent neurons, rodent brain cell
aggregates and human neuronal cell lines. Unless otherwise cited, this presentation summarizes
published results from the ACuteTox project [34,35]. Cell viability in the neural systems after
exposure to the agents for 24 – 48 hours did not differ from that in non neural cell lines,
suggesting that the neuronal cytotoxicity model did not correct the outlier chemicals found in
the NRU-3T3 cytotoxicity assay versus human LC50 correlation [34]. 28 out of 58 tested
chemicals were recognized by the GABAA receptor (GABAAR) assay (a radiometric assay
determining 36Cl− influx in primary cultured neurons) and 10 out of 23 chemicals were
recognized by the GABA transport assay (a radiometric assay measuring [3H]GABA uptake
in primary cultured neurons). In contrast, other neurochemical assays (fluorescence assays for
acetylcholine and glutamate receptor function, spectrophotometric assay for
acetylcholinesterase activity and radiometric/chromatographic assay for glutamate transport)
were very specific and recognized few compounds from the reference list. A more general
assay for assessing neuronal excitability (a fluorescence-based assay measuring changes in cell
membrane potential (CMP) in the human neuronal cell line SH-SY5Y) recognized 22 out of
58 chemicals. The combination of the CMP and GABAAR assays generated alerts (the
neurotoxic endpoints were more sensitive than the cytotoxic endpoint) for outliers (Figure 4)
and improved the in vitro predictability of human acute toxicity. The R2 values for the
correlation of in vitro data vs. human LC50 values were estimated to 0.57 for only the general
cytotoxicity data and 0.64 when considering cytotoxicity data in combination with alerts
identified from the CMP+GABAAR assays. By using appropriate agonists and
pharmacological agents, the GABAAR and the CMP assays may cover most of the membrane-
based neurotoxicity pathways. As an advantage for the use of these in vitro testing of neural
endpoints, both the GABAAR and the CMP assays were performed in a short period of time
(10 and 2 minutes, respectively). However, the drawback of using a highly energetic
radionuclide in the GABAAR assay should be overcome by the use of less energetic isotopes
or even, non radiometric techniques.
In addition to the GABAAR and CMP assays, genomic and metabolic endpoints were analyzed
in a multi-endpoint assay after exposure to rodent brain cell aggregate cultures and the
expression of the stress gene marker caspase 3 was determined in primary cultured neurons.
Aschner et al. Page 6
Neurotoxicology. Author manuscript; available in PMC 2011 September 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
The multi-endpoint determining changes in the mRNA of NF-H, GFAP, MBP and HSP32, as
well as in the total mRNA level and glucose consumption in the brain cell aggregate cultures
that were exposed for 48 hours to the tested chemicals resulted to be the most sensitive
endpoints producing alerts for severe outliers like digoxin, lindane, malathion and parathion.
Furthermore, the caspase-3 mRNA expression gave a good estimate of the human LC50 for a
set of the chemicals tested, correcting severe outliers like atropine, digoxin and malathion
[34].
Conclusions
In conclusion, the assays developed in ACuteTox project have provided alerts for all the outliers
evolved from the cytotoxicity – human LC50 correlation. The combined genomic and metabolic
biomarkers analyzed in the brain cell aggregate cultures were very sensitive endpoints,
generating most alerts. The combination of the GABAAR and CMP assays identified correct
outliers and improved the prediction of human lethal toxicity. These two endpoints cover most
of the membrane-based neurotoxicity. As a whole, it is foreseen that the ACuteTox project will
yield “alert” tests to indicate when a cytotoxicity-based test result may not be valid and
“corrector” tests to improve the predictive capabilities of a test strategy. A capacity to indicate
when a cytotoxicity-based in vitro approach may be insufficient and that additional testing is
required or that a certain compound is beyond its predictive capabilities represents an important
step forward for in vitro methods.
Erythropoietin, Desferroxamine and Tiron are Protective against Vanadium-
Induced Demyelination and Oxidative Stress in the Rat Brain
Introduction
Environmental pollution from fossil fuel burning and the subsequent release of finely
particulate vanadium compounds in the Arabian gulf [36] and Nigeria's Niger Delta [37]has
been on the increase with minimal studies done on both the short and long term effects on the
brain. Hypomyelination and or myelin destruction from lipid peroxidation has been implicated
in part to be responsible for the phenotypic expressions of neuromuscular and behavioral
deficits seen in vanadium toxicosis [38]. The present study assessed novel cellular changes
caused by sodium metavanadate (SMV) in astrocyte culture cells and the neuroprotective
effects of antidotes desferroxamine (DFO), tiron and erythropoietin (EPO) on vanadium-
induced astrogliosis and demyelination.
Studies on the in vitro and in vivo Neurotoxicity of Vanadium
The effects of vanadium treatment (150 μM for 6 hours) on reactive oxygen species (ROS)
generation, cellular hypoxia and erythropoietin (EPO) expression were assessed in primary rat
astrocytes cultures. ROS generation was determined with the dichlorofluorescein (DCF) assay
[measured as relative fluorescence unit (RFU)]. Protein expression was determined by western
blot (WB) analysis, using HIF-1 α (Hypoxia Induction Factor) and EPO antibodies (Santa
Cruz). We also treated 15-day-old Sprague-Dawley rats (n=5) with 3mg/kg SMV for seven
days; three groups were similarly treated, but were given DFO (300 mg/kg/day), tiron (606
mg/kg/day) or EPO (5,000 U/kg/day) as antidotes concurrently for six days (one day after
vanadium treatment) with appropriate controls. Glial fibrillary acidic protein (GFAP)
immunohistochemistry was observed in the corpus callosum while myelin basic protein (MBP)
was quantified with WB analysis.
There was a significant increase in ROS generation in vanadate treated primary astrocyte
cultures compared with controls (Figure 5) including up-regulation in HIF-1 α and EPO
expressions as seen by WB analysis (Figure 6). There was also a significant increase in GFAP
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immunoreactivity in the corpus callosum (Figure 7) and a decrease in MBP quantification in
brains of vanadium treated rats compared to controls (Figure 8); these observations were
significantly (P<0.05) attenuated in rats receiving the antidotes DFO and EPO, or tiron and
EPO.
In this study, vanadium induced the production of reactive oxygen species (ROS); this causes
the cells to undergo hypoxia, the onset of which leads to vanadate-induced expression of
HIF-1α [39]]. In other cells, such as the kidney cells and prostate cancer; HIF 1 α upregulation
leads to increased EPO expression [40]. EPO has been shown to be expressed in the brain
[41]; in mammalian tissue, discrepancy between oxygen supply and utilization leads to hypoxia
which induces a variety of specific adaptation mechanisms including the activation of HIF,
which, in turn, has a modulatory role on hypoxically-related genes, such as those encoding for
EPO [42]. In ischemia, the de novo up regulation of EPO in the brain creates a protective effect
against neuronal injury. Though vanadium causes neuronal pathologies and neurobehavioral
deficits [38] in vivo, induces oxidative stress and cellular hypoxia in brain cell cultures [43].
The role EPO plays at the cellular, local and systemic level during vanadium neurotoxicosis
remains unknown. Our work has shown that vanadium induced HIF-1 α expression can lead
to EPO upregulation in primary astrocytes which is indicative of an endogenous protective
mechanism in the neuroglia. This current work also shows that systemic administration of
antidotes can modulate vanadium-induced neuropathologies. The increased expression of
GFAP seen after vanadium treatment was significantly attenuated by the antidotes DFO and
EPO, but not by tiron, while the reduced MBP expression caused by vanadium administration
was significantly reversed by tiron and EPO, indicating that EPO was effective in both
instances. These actions of EPO are consistent with the fact that EPO has anti-inflammatory
and antioxidative effects, and prevents lipid peroxidation [44]. While in theory, it is expected
that vanadium entry into the brain will lead to increased generation of ROS, which will
concurrently be responsible for increased GFAP expression, lipid peroxidation and then
demyelination, the fact that DFO in vivo was able to attenuate the increased GFAP expression
after vanadate treatment, but not the demyelinating process and vice-versa for tiron may be
indicative of other independent pathways between lipid peroxidation and demyelination caused
by vanadate neurotoxicosis.
Conclusions
In conclusion, this work demonstrates the utility of primary astrocyte cultures in screening the
effects of vandate on cellular responses, as well as novel information on vandate's ability to
induce increased expression of EPO in astrocyte cell cultures and that antidotes, such as
exogenous EPO can attenuate astrogliosis and demyelination caused by vanadate
neurotoxicosis.
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Figure 1.
DA neurons visualized in adult C. elegans with DAT-1∷GFP transcriptional fusions. Arrows
point to cephalic sensilla (CEP), anterior deirids (ADE) and posterior deirids (PDE) neurons.
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Figure 2.
Effects on acetylcholinesterase activity of 0.29μM (100 ng/ml) of chlorpyrifos for five days
post-fertilization and AChE morpholino.
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Figure 3.
Effects on delayed spatial alternation choice accuracy of 0.29μM (100 ng/ml) of chlorpyrifos
for five days post-fertilization [30] and AChE morpholino, percent correct difference from
control mean (mean ± SEM).
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Figure 4.
Neurotoxicity alerts determined by the combination of the GABAAR and cell membrane
potential assay (CMP). Blue bars represent the lowest EC50/LEC values for the GABAAR
assay (performed in primary neuronal cultures) or the CMP assay (performed in SH-SY5Y
cells) after acutely exposure to the reference chemicals. Red bars represent IC50 values for the
NRU cytotoxicity test (performed in 3T3 cells) from Sjöström et al. (2008). Asterisks indicate
neurotoxic alerts (significant effects on the GABAAR/CMP assays) were produced at
concentrations at least one order of magnitude lower than those producing cytotoxicity. Arrows
indicate outlier compounds in the NRU-3T3 cytotoxicity assay vs human LC50 values
correlation.
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Figure 5.
Analysis of intracellular reactive oxygen (ROS) generation in primary rat astrocytes after
vanadium treatment for six hours using the dichlorofluorescein dye. Vanadium treatment
resulted in significant increase in detectable ROS generation (P<0.001).
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Figure 6.
Primary astrocytes in culture were treated with sodium metavanadate (150 μM) for six hours.
Total cellular protein extracts were obtained and transferred to nitrocellulose membranes which
were separately incubated with antibodies against HIF-1α (120 kDa) and EPO (37 kDa) (Santa
Cruz). Results show up-regulation of HIF-1α (left block) and EPO (right block) when compared
to their respective controls.
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Figure 7.
Treatment of rat cells 3mg /kg of SMV for seven days caused increased GFAP expression (top
right) compared to controls (top left). The staining caused by vanadate in was markedly
attenuated by antidotes DFO and EPO (bottom left and right respectively) but not by tiron
(bottom center).
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Figure 8.
Treatment of rat with3mg /kg of SMV for seven days led to decreased myelin content (G2)
compared to controls (G1). Antidotes tiron and EPO (G4and5) when administered with
vanadate caused a significant increase in myelin quantity compared to treated group but not
the case with DFO (G3).
Aschner et al. Page 19
Neurotoxicology. Author manuscript; available in PMC 2011 September 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
